Asco 2019 event analyser – low-key meeting belies some huge stock moves
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Asco 2019 – tepotinib and capmatinib fight over a new lung cancer niche
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Pharma news over the Christmas period
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
Ash 2018 – Immunogen makes its case for a Jazz gig
The first day of the haematology conference sees first-in-human data from two antibody-drug conjugates belonging to Immunogen, a company eager to draw a line under a…
